Novartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range.
ProQR validates RNA editing platform and raises $59.2m
Latest NewsProQR has reported the first clinical target-engagement data for its Axiomer RNA editing platform, while pricing a share offering and concurrent private placement that includes existing partner Eli Lilly.
Recordati secures ex-U.S. rights to Ionis’ Alexander disease therapy
Latest NewsItalian pharma Recordati has entered into a license agreement with Ionis Pharmaceuticals, Inc. for exclusive development and marketing rights to zilganersen, an investigational RNA-targeted medicine for the treatment of Alexander disease (AxD), in all countries outside the U.S.
ADC Therapeutics cuts 17% of staff after safety setback
Latest NewsADC Therapeutics will cut about 17% of its global workforce as it tries to preserve cash and keep Zynlonta’s regulatory strategy on track after a difficult Phase III readout.
Novartis signs up to $1.9bn deal to tap Antares’ undruggable-target engine
Latest NewsNovartis has signed a multi-target oncology discovery deal with Antares Therapeutics, paying $105m upfront for access to the Boston biotech’s small-molecule discovery engine. The agreement could bring Antares up to $1.8bn more in option, development, regulatory and commercial milestones, plus tiered royalties on global net sales that could reach the low double-digit range.
Leyden Labs adds €40m for intranasal flu prevention
Latest NewsDutch biotech Leyden Labs has raised €40m from a group of investors to advance its nasal spray approach for protection against influenza and other respiratory viruses.
RQ Bio raises $115m for long-acting flu antibody
Latest NewsLondon’s RQ Bio, a private biotech developing long-acting antibody therapeutics to prevent flu, has raised $115 million (£85.5 million/€101 million) in its Series A financing.
Thalia buys Sanmirna, becomes a clinical-stage RNA company
Latest NewsThalia Therapeutics is acquiring Sanmirna Therapeutics for an initial £3.675 million and up to £13 million in milestone payments, adding the clinical-stage acute myeloid leukemia (AML) candidate miRisten and transforming the company from a preclinical platform into a clinical-stage RNA therapeutics company.
Merck launches build-to-buy Saturnus Bio with $50m
Latest NewsMerck KGaA has partnered with Versant Ventures to launch Saturnus Bio, a new biotech developing precision medicines for rare genetic cardiomyopathies.
TRIMTECH extends seed round to $47M for protein degradation drugs
Latest NewsUK-based TRIMTECH Therapeutics has raised an additional $14 million, bringing its total seed financing to $47 million.
Indivumed, ready to set sail to the clinic
slider, Sponsored PublicationsWith the separation from the biobank service business, Hamburg-based Indivumed has repositioned itself as a therapeutics biotech. Its earlier work remains the core of its medical knowledge and the source of novel targets. To advance the already pre-validated selection more quickly, the company is now looking for partners. The response has been strong, say Matthias Evers and Hartmut Juhl in conversation with European Biotechnology Magazine.